Skip to main content
Article thumbnail
Location of Repository

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes

By Marc K Israel, Eva Istvan and Michelle A Baron

Abstract

The increasing prevalence of type 2 diabetes provides impetus for both development of new drugs to improve glycemic control and for reconsideration of treatment strategies with existing agents. Combination therapy with complementary drug classes that act on different aspects of glycemic control has been a particularly effective strategy. This work reviews the published literature reporting efficacy and safety/tolerability of nateglinide, a rapid-onset insulinotropic agent with a predominant effect to reduce postprandial glucose, when combined with metformin, a first-line agent that suppresses hepatic glucose production and thereby reduces fasting plasma glucose. The nateglinide/metformin combination has consistently been found to be both efficacious and well tolerated, whether given as initial combination therapy in drug-naïve patients or when added to metformin monotherapy. Maximum efficacy (Δ glycosylated hemoglobin [HbA1c]= −1.4% to −1.9%, sustained for up to 2 years of treatment) was seen in studies of drug-naïve patients in whom pharmacotherapy was initiated with the combination of nateglinide and metformin, and modest reductions in HbA1c (Δ = −0.5% to −1.2%, sustained for up to 24 weeks) were found when nateglinide was added to ongoing metformin monotherapy

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2663444
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). Clinical pharmacokinetics of nateglinide: a rapidlyabsorbed, short-acting insulinotropic agent. Clin Pharmacokinet,
    2. (1996). Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al. Diabetes Care,
    3. (2005). Disease Control and Prevention. National diabetes fact sheet: United States,
    4. (2006). Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review.
    5. (2007). Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
    6. (2003). Effi cacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    7. (2004). Effi cacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin,
    8. (2003). Effi cacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. Exp Clin Endocrinol Diabetes,
    9. (1989). Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.
    10. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care,
    11. (2007). Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way.
    12. (2007). Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med,
    13. (2006). Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    14. (1995). Multicenter Metformin Study Group.
    15. (2000). Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care,
    16. (2004). Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84. Diabetes Obes Metab,
    17. (2002). Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab,
    18. (2007). Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    19. (2008). Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. Diabetes Obes Metab,
    20. (1999). Pharmacologic therapy for type 2 diabetes mellitus.
    21. (2005). PRESERVE-β: two-year effi cacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care,
    22. (2001). Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des,
    23. (2004). Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care,
    24. (1999). The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
    25. (2000). The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev,
    26. (2003). The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.
    27. (2001). The role of new antiepileptic drugs.
    28. (2002). Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.